Discovery

Myeloid cell transplantation rescues Friedreich's ataxia through mitochondrial transfer in mice

Myeloid cell transplantation rescues Friedreich's ataxia through mitochondrial transfer in mice

Hematopoietic transplantation can rescue neurological and cardiac deficits in a mouse model of Friedreich's ataxia (FA) — not by replacing diseased neurons or cardiomyocytes directly, but by delivering functional mitochondria to those cells through donor-derived myeloid cells, according to a study published August 15 in Nature Communications. The finding positions bone marrow transplantation as a potential mitochondrial delivery platform for inherited metabolic diseases affecting cell types that cannot themselves be transplanted.

The work, led by Natalia Gomez-Ospina at Stanford University's Department of Pediatrics and Stanford Institute for Stem Cell and Regenerative Medicine, addresses a core limitation of existing FA therapies: none directly correct the underlying bioenergetic defect across neurons and cardiomyocytes, the cell populations responsible for the disease's progressive neurological decline and cardiomyopathy.

FA is caused by frataxin deficiency, which impairs iron-sulfur cluster assembly and mitochondrial oxidative phosphorylation (OXPHOS). Using frataxin-deficient mice, the researchers found that hematopoietic transplantation improved survival, locomotion, strength, coordination, and cardiac function in both male and female animals. Recipient tissues showed increased expression of OXPHOS and ATP synthesis genes alongside elevated mitochondrial protein abundance, consistent with functional mitochondrial rescue rather than immune reconstitution alone.

Mechanistic experiments traced the rescue effect to mitochondrial transfer from donor-derived microglia and macrophages to host CNS and cardiac cells. In frataxin-deficient cells cultured in vitro, donor myeloid cells rescued respiratory capacity, while preventing direct contact between donor and recipient cells abolished the effect, indicating that rescue requires cell-cell contact rather than diffusible secreted factors. Frataxin-deficient recipient cells also showed enhanced mitochondrial uptake, consistent with metabolic stress increasing their acquisition of healthy organelles.

The AllSci BriefSystematic R&D and deal news. Daily.

The competitive landscape for FA has shifted substantially since omaveloxolone (Skyclarys), an Nrf2 activator developed by Reata Pharmaceuticals and now owned by Biogen, received FDA approval in 2023 as the first approved FA therapy. Gene therapy approaches seek more direct frataxin restoration, led by Lexeo Therapeutics' AAV-based LX2006 for FA cardiomyopathy. Phase I/II results were published in JAMA Cardiology in June 2026, while Lexeo has designed the pivotal SUNRISE-FA 2 study to


Access the AllSci platform to explore the science behind the news.


Spot something wrong? Report an issue with this article